In this review article we have reported a series of hybrid compounds characterized by the presence of a α-halogenocryloyl alkylating moiety of low chemical reactivity, linked to known antitumor agents or their active moieties. Among them, brostallicin (PNU-166196), was selected for clinical development and is now undergoing Phase II studies in patients with advanced or metastatic soft tissue sarcoma. © 2009 Bentham Science Publishers Ltd.

alpha-Halogenoacrylic Derivatives of Antitumor Agents

ROMAGNOLI, Romeo;BARALDI, Pier Giovanni;PRETI, Delia
2009

Abstract

In this review article we have reported a series of hybrid compounds characterized by the presence of a α-halogenocryloyl alkylating moiety of low chemical reactivity, linked to known antitumor agents or their active moieties. Among them, brostallicin (PNU-166196), was selected for clinical development and is now undergoing Phase II studies in patients with advanced or metastatic soft tissue sarcoma. © 2009 Bentham Science Publishers Ltd.
Romagnoli, Romeo; Baraldi, Pier Giovanni; Cruz Lopez, O.; Lopez Cara, C.; Preti, Delia
File in questo prodotto:
Non ci sono file associati a questo prodotto.

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11392/1377635
 Attenzione

Attenzione! I dati visualizzati non sono stati sottoposti a validazione da parte dell'ateneo

Citazioni
  • ???jsp.display-item.citation.pmc??? ND
  • Scopus 12
  • ???jsp.display-item.citation.isi??? 13
social impact